sales@targetmol.com (US) / info@targetmol.com    Tel: (781) 999-4286 / (857) 239-0968
Home > c-Met
c-Met
Cat.No. Product Name Information Area
T4260 INCB28060 2HCl INCB-28060(free base) is a novel, ATP-competitive inhibitor of c-MET kinase with an I... cancer
T3455 LY2801653 LY2801653 is an orally available, small molecule inhibitor of the proto-oncogene c-Me... Cancer
T6907 NPS-1034 NPS-1034 is a dual Met/Axl inhibitor with IC50 of 48 nM and 10.3 nM, respectively. Others
T6517 Golvatinib (E7050) Golvatinib is an orally bioavailable dual kinase inhibitor of c-Met (hepatocyte growt... Cancer
T6378 AMG-458 AMG 458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Me... Cancer
T6260 AMG-208 AMG 208 is a highly selective c-Met inhibitor with IC50 of 9 nM. Phase 1. Cancer
T6154 SU11274 SU11274(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on P... Cancer
T6128 PHA-665752 PHA-665752 is an effective, specific and ATP-competitive c-Met inhibitor (IC50: 9 nM)... Cancer
T6121 Tepotinib (EMD 1214063) Tepotinib is an inhibitor of MET tyrosine kinase with potential antineoplastic activi... Cancer
T6117 Tivantinib (ARQ 197) Tivantinib is an orally bioavailable small molecule inhibitor of c-Met with potential... Cancer
T6095 JNJ-38877605 JNJ-38877605 is an ATP-competitive c-Met inhibitor (IC50: 4 nM), 600-fold selective f... Cancer
T6094 MK-2461 MK-2461 is a novel ATP-competitive multitargeted inhibitor of activated c-Met with a ... Cancer
T3113 Foretinib Foretinib is an ATP-competitive inhibitor of HGFR and VEGFR, with IC50 of 0.4 nM and ... Cancer
T2699 BMS-777607 BMS-777607 is a Met-related inhibitor for c-Met/Axl/Ron/Tyro3 (IC50: 3.9/1.1/1.8/4.3 ... Endocrine system
T2680 NVP-BVU972 NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM. Cancer
T2676 PF-04217903 MET Tyrosine Kinase Inhibitor PF-04217903 is an orally bioavailabe, small-molecule ty... Cancer
T2456 Tivozanib Tivozanib is an orally bioavailable inhibitor of vascular endothelial growth factor r... Cancer
T2419 BMS794833 BMS-794833 is a potent ATP competitive inhibitor of Met/VEGFR2; a prodrug of BMS-8173... Cancer
T2349 BMS-754807 Dual IGF-1R/InsR Inhibitor BMS-754807 is an oral small molecule inhibitor of insulin-... Cancer
T2293 SGX-523 SGX-523 is a selective Met inhibitor (IC50: 4 nM), no inhibitory to Abl, BRAFV599E, p... Cancer
T2282 RPI-1 RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor.? Cancer
T2054 Altiratinib Altiratinib(DCC-2701) is a novel c-MET/TIE-2/VEGFR inhibitor; effectively reduce tumo... Cancer
T1963 INCB28060(Capmatinib) Capmatinib is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)wit... Other
T1661 Crizotinibhot Crizotinib is a Kinase Inhibitor. The mechanism of action of crizotinib is as a Cytoc... Cancer
T6351 MGCD-265 MGCD-265-analog (structurally related to MGCD-265) is an orally bioavailable multitar... Cancer
1